STL Index for: Mariana A. Phillips

Most molluscum contagiosum lesions resolve on their own, but symptomatic or cosmetically troubling cases have long been managed with off-label agents and destructive procedures. That changed with the FDA approval of cantharidin 0.7% drug-device applicator in 2023 and berdazimer 10.3% gel in 2024. This review examines the trial evidence behind both, compares them with potassium hydroxide, salicylic acid, cryotherapy, curettage, and pulsed dye laser, and addresses the treatment gaps that remain in immunocompromised patients and those with atopic dermatitis.

Read about current and emerging hyperhidrosis treatments including sofpironium bromide, glycopyrronium wipes, botulinum toxin, targeted alkali thermolysis, microwave therapy, and laser options.

Deuruxolitinib (FDA-approved July 2024) is an oral JAK1/JAK2 inhibitor for severe alopecia areata. Learn about its mechanism, THRIVE-AA trial results showing rapid hair regrowth, safety profile, and how it compares to baricitinib and ritlecitinib.

Neoadjuvant cemiplimab has shown promising results for resectable cutaneous squamous cell carcinoma where surgery may result in significant morbidity. Phase 2 studies demonstrated pathological complete response rates of 51% with event-free survival of 89% at 12 months. The treatment was well-tolerated and may improve surgical outcomes by reducing tumor burden before resection, offering a valuable option for advanced disease.

Toxic epidermal necrolysis (TEN) is an immune-mediated, severe cutaneous adverse drug reaction characterized by epidermal detachment affecting greater than 30% body surface area.

HPV vaccines (Gardasil and Cervarix) may indeed have a therapeutic role in patients who suffer from dermatologic conditions that are associated with various strains of HPV.

Janus kinase inhibitors, also known as JAK inhibitors or jakinibs, represent a new class of medication that have broad potential to treat dermatologic disease.

Recent advances in the treatment of hereditary angioedema, particularly in the last decade has been promising. This paper reviews the mechanisms, efficacy, and adverse reactions associated with these new treatment medications.